Cesare Gridelli

3.8k total citations · 3 hit papers
37 papers, 2.9k citations indexed

About

Cesare Gridelli is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Cesare Gridelli has authored 37 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Cesare Gridelli's work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Research Studies (14 papers) and Colorectal Cancer Treatments and Studies (12 papers). Cesare Gridelli is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Research Studies (14 papers) and Colorectal Cancer Treatments and Studies (12 papers). Cesare Gridelli collaborates with scholars based in Italy, United States and Germany. Cesare Gridelli's co-authors include Filippo de Marinis, Giorgio V. Scagliotti, Lucio Crinò, Monica Rinaldi, Maurizio Tonato, Vincenzo Adamo, Francesco Di Costanzo, M. Marangolo, A. Ceribelli and Serafino Ricci and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Cesare Gridelli

37 papers receiving 2.8k citations

Hit Papers

Phase III Randomized Trial Comparing Three Platinum-Based... 2002 2026 2010 2018 2002 2012 2013 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
    2002 739 citations Giorgio V. Scagliotti, Filippo de Marinis et al. Journal of Clinical Oncology profile →
  2. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
    2012 447 citations Luis Paz‐Ares, Filippo de Marinis et al. The Lancet Oncology profile →
  3. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
    2013 438 citations Luis Paz‐Ares, Filippo de Marinis et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cesare Gridelli Italy 18 2.4k 2.1k 527 270 179 37 2.9k
Miloš Pešek Czechia 21 1.7k 0.7× 1.6k 0.8× 650 1.2× 408 1.5× 133 0.7× 110 2.4k
Purvish Parikh India 9 2.1k 0.9× 1.8k 0.8× 521 1.0× 412 1.5× 186 1.0× 21 2.6k
J. Bérille France 16 2.3k 1.0× 2.4k 1.1× 484 0.9× 283 1.0× 242 1.4× 48 3.1k
Daniel T. Milton United States 16 1.9k 0.8× 1.6k 0.8× 587 1.1× 383 1.4× 125 0.7× 27 2.4k
C. Anger United Kingdom 3 2.6k 1.1× 2.3k 1.1× 945 1.8× 471 1.7× 167 0.9× 10 3.3k
Mauro Zukin Brazil 13 2.8k 1.2× 2.4k 1.1× 748 1.4× 519 1.9× 207 1.2× 38 3.5k
Annetta Krebs United States 8 1.9k 0.8× 2.0k 0.9× 723 1.4× 395 1.5× 131 0.7× 8 2.8k
Patrick Peterson United States 21 2.2k 0.9× 1.8k 0.8× 472 0.9× 310 1.1× 166 0.9× 55 2.6k
Michael McCleod United States 17 1.7k 0.7× 2.5k 1.2× 410 0.8× 276 1.0× 227 1.3× 44 3.0k

Countries citing papers authored by Cesare Gridelli

Since Specialization
Citations

This map shows the geographic impact of Cesare Gridelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cesare Gridelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cesare Gridelli more than expected).

Fields of papers citing papers by Cesare Gridelli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cesare Gridelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cesare Gridelli. The network helps show where Cesare Gridelli may publish in the future.

Co-authorship network of co-authors of Cesare Gridelli

This figure shows the co-authorship network connecting the top 25 collaborators of Cesare Gridelli. A scholar is included among the top collaborators of Cesare Gridelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cesare Gridelli. Cesare Gridelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gridelli, Cesare, Solange Peters, Vamsidhar Velcheti, Ilaria Attili, & Filippo de Marinis. (2023). Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT). ESMO Open. 8(2). 101192–101192. 17 indexed citations
2.
3.
Piccirillo, Maria Carmela, Laura Bonanno, Marina Chiara Garassino, et al.. (2021). 1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial. Annals of Oncology. 32. S950–S950. 8 indexed citations
4.
5.
Maïo, Massimo Di, Maria Carmela Piccirillo, Gennaro Daniele, et al.. (2014). Symptomatic Toxicities Experienced During Anti-Cancer Treatment: Comparison of Patients' and Physicians' Reporting in Three Randomized Controlled Trials (Rcts). Annals of Oncology. 25. iv517–iv517. 1 indexed citations
6.
Maïo, Massimo Di, Filippo de Marinis, Fred R. Hirsch, & Cesare Gridelli. (2014). Diagnostic and therapeutic issues for patients with advanced non-small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (Review). International Journal of Oncology. 45(2). 509–515. 11 indexed citations
7.
Paz‐Ares, Luis, Filippo de Marinis, Mircea Dediu, et al.. (2013). PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 31(23). 2895–2902. 438 indexed citations breakdown →
8.
Paz‐Ares, Luis, Filippo de Marinis, Mircea Dediu, et al.. (2012). Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. The Lancet Oncology. 13(3). 247–255. 447 indexed citations breakdown →
9.
Rossi, Antônio, Serena Ricciardi, Paolo Maione, Filippo de Marinis, & Cesare Gridelli. (2009). Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer. 66(2). 141–149. 51 indexed citations
10.
Gridelli, Cesare, Antônio Rossi, Paolo Maione, et al.. (2009). Vascular Disrupting Agents: A Novel Mechanism of Action in the Battle Against Non-Small Cell Lung Cancer. The Oncologist. 14(6). 612–620. 58 indexed citations
11.
Cascone, Tina, Cesare Gridelli, & Fortunato Ciardiello. (2007). Combined targeted therapies in non-small cell lung cancer: a winner strategy?. Current Opinion in Oncology. 19(2). 98–102. 21 indexed citations
12.
Petris, Luigi De, Lucio Crinò, Giorgio V. Scagliotti, et al.. (2006). Treatment of advanced non-small cell lung cancer. Annals of Oncology. 17. ii36–ii41. 34 indexed citations
13.
Mali, P, Filippo de Marinis, C. Manegold, et al.. (2004). Single agent oral vinorelbine (NVB) in advanced non-small cell lung cancer (NSCLC) in the elderly: Patient benefit improvement by weekly schedule. Journal of Clinical Oncology. 22(14_suppl). 7120–7120. 3 indexed citations
14.
15.
Gridelli, Cesare, S. Cigolari, Ciro Gallo, et al.. (2001). Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients. Lung Cancer. 31(2-3). 277–284. 103 indexed citations
16.
Gridelli, Cesare, Federica Perrone, Fabrizio Nelli, Sara Ramponi, & Filippo de Marinis. (2001). Quality of life in lung cancer patients. Annals of Oncology. 12. S21–S25. 51 indexed citations
17.
Rinaldi, Monica, Lucio Crinò, Giorgio V. Scagliotti, et al.. (2000). A three-week schedule of gemcitabine–cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: A phase II randomized trial. Annals of Oncology. 11(10). 1295–1300. 46 indexed citations
18.
Gridelli, Cesare, Cesare Guida, Emiddio Barletta, et al.. (2000). Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study. Lung Cancer. 29(2). 131–137. 22 indexed citations
19.
Gridelli, Cesare, L. Frontini, Emiddio Barletta, et al.. (2000). Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literature.. PubMed. 20(2B). 1077–84. 10 indexed citations
20.
Gridelli, Cesare, Franco Perrone, Ciro Gallo, et al.. (1997). Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. European Journal of Cancer. 33(3). 392–397. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miloš Pešek Breakdown of academic impact, for papers by Purvish Parikh Breakdown of academic impact, for papers by J. Bérille Breakdown of academic impact, for papers by Daniel T. Milton Breakdown of academic impact, for papers by C. Anger Breakdown of academic impact, for papers by Mauro Zukin Breakdown of academic impact, for papers by Annetta Krebs Breakdown of academic impact, for papers by Patrick Peterson Breakdown of academic impact, for papers by Michael McCleod
Rankless by CCL
2026